Background Pulmonary fibrosis (PF) caused by interstitial lung diseases (ILDs) affects up to 0.1% of the global population. There is growing global interest in PF, evident from a nearly threefold ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Predicted survival has gone up from 46 years in 2015 to ...

Fibrosis of the lungs is often a silent disease until it's too late. By the time patients are diagnosed, the scarring of their lung tissue is already advanced, and current treatments offer little more ...

In patients with CF, pre-transplant PH is associated with improved early post-transplant survival, but with poorer outcomes after 3 years.

Because evidence gaps in idiopathic pulmonary fibrosis research hinder demonstration of antifibrotic therapies’ impact on patient quality of life (QOL), integrating validated health-related QOL ...